ID   CDK9_HUMAN              Reviewed;         372 AA.
AC   P50750; Q5JU24; Q5JU25; Q5U006; Q96TF1;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 3.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=Cyclin-dependent kinase 9;
DE            EC=2.7.11.22;
DE            EC=2.7.11.23;
DE   AltName: Full=C-2K;
DE   AltName: Full=Cell division cycle 2-like protein kinase 4;
DE   AltName: Full=Cell division protein kinase 9;
DE   AltName: Full=Serine/threonine-protein kinase PITALRE;
DE   AltName: Full=Tat-associated kinase complex catalytic subunit;
GN   Name=CDK9; Synonyms=CDC2L4, TAK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8170997; DOI=10.1073/pnas.91.9.3834;
RA   Grana X., de Luca A., Sang N., Fu Y., Claudio P.P., Rosenblatt J.,
RA   Morgan D.O., Giordano A.;
RT   "PITALRE, a nuclear CDC2-related protein kinase that phosphorylates
RT   the retinoblastoma protein in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:3834-3838(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-231.
RX   PubMed=7695608; DOI=10.1006/bbrc.1995.1375;
RA   Best J.L., Presky D.H., Swerlick R.A., Burns D.K., Chu W.;
RT   "Cloning of a full-length cDNA sequence encoding a cdc2-related
RT   protein kinase from human endothelial cells.";
RL   Biochem. Biophys. Res. Commun. 208:562-568(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-231.
RX   PubMed=10903437; DOI=10.1016/S0378-1119(00)00215-8;
RA   Liu H., Rice A.P.;
RT   "Genomic organization and characterization of promoter function of the
RT   human CDK9 gene.";
RL   Gene 252:51-59(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH HIV TAT.
RX   PubMed=9491887; DOI=10.1016/S0092-8674(00)80939-3;
RA   Wei P., Garber M.E., Fang S.-M., Fischer W.H., Jones K.A.;
RT   "A novel CDK9-associated C-type cyclin interacts directly with HIV-1
RT   Tat and mediates its high-affinity, loop-specific binding to TAR
RT   RNA.";
RL   Cell 92:451-462(1998).
RN   [9]
RP   FUNCTION.
RX   PubMed=9857195; DOI=10.1093/emboj/17.24.7395;
RA   Wada T., Takagi T., Yamaguchi Y., Watanabe D., Handa H.;
RT   "Evidence that P-TEFb alleviates the negative effect of DSIF on RNA
RT   polymerase II-dependent transcription in vitro.";
RL   EMBO J. 17:7395-7403(1998).
RN   [10]
RP   IDENTIFICATION IN A COMPLEX WITH CCNT1 AND CCNT2.
RX   PubMed=9499409; DOI=10.1101/gad.12.5.755;
RA   Peng J.-M., Zhu Y., Milton J.T., Price D.H.;
RT   "Identification of multiple cyclin subunits of human P-TEFb.";
RL   Genes Dev. 12:755-762(1998).
RN   [11]
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH HTATSF1; CCNT1; RNA POL
RP   II; SUPT5H AND NCL.
RX   PubMed=10393184; DOI=10.1093/emboj/18.13.3688;
RA   Parada C.A., Roeder R.G.;
RT   "A novel RNA polymerase II-containing complex potentiates Tat-enhanced
RT   HIV-1 transcription.";
RL   EMBO J. 18:3688-3701(1999).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH CCNK.
RX   PubMed=10574912; DOI=10.1074/jbc.274.49.34527;
RA   Fu T.J., Peng J., Lee G., Price D.H., Flores O.;
RT   "Cyclin K functions as a CDK9 regulatory subunit and participates in
RT   RNA polymerase II transcription.";
RL   J. Biol. Chem. 274:34527-34530(1999).
RN   [13]
RP   FUNCTION.
RX   PubMed=10912001; DOI=10.1016/S1097-2765(00)80272-5;
RA   Wada T., Orphanides G., Hasegawa J., Kim D.-K., Shima D.,
RA   Yamaguchi Y., Fukuda A., Hisatake K., Oh S., Reinberg D., Handa H.;
RT   "FACT relieves DSIF/NELF-mediated inhibition of transcriptional
RT   elongation and reveals functional differences between P-TEFb and
RT   TFIIH.";
RL   Mol. Cell 5:1067-1072(2000).
RN   [14]
RP   FUNCTION.
RX   PubMed=10757782; DOI=10.1128/MCB.20.9.2970-2983.2000;
RA   Ivanov D., Kwak Y.T., Guo J., Gaynor R.B.;
RT   "Domains in the SPT5 protein that modulate its transcriptional
RT   regulatory properties.";
RL   Mol. Cell. Biol. 20:2970-2983(2000).
RN   [15]
RP   PHOSPHORYLATION BY PKA, AUTOPHOSPHORYLATION, PHOSPHORYLATION AT
RP   SER-347; THR-350; SER-353; THR-354 AND SER-357, INTERACTION WITH HIV
RP   TAT, AND MUTAGENESIS OF 347-SER--SER-357 AND ASP-167.
RX   PubMed=10958691; DOI=10.1128/MCB.20.18.6958-6969.2000;
RA   Garber M.E., Mayall T.P., Suess E.M., Meisenhelder J., Thompson N.E.,
RA   Jones K.A.;
RT   "CDK9 autophosphorylation regulates high-affinity binding of the human
RT   immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA.";
RL   Mol. Cell. Biol. 20:6958-6969(2000).
RN   [16]
RP   FUNCTION, AND MUTAGENESIS OF ASP-167 AND THR-186.
RX   PubMed=11145967; DOI=10.1074/jbc.M010908200;
RA   Kim J.B., Sharp P.A.;
RT   "Positive transcription elongation factor B phosphorylates hSPT5 and
RT   RNA polymerase II carboxyl-terminal domain independently of cyclin-
RT   dependent kinase-activating kinase.";
RL   J. Biol. Chem. 276:12317-12323(2001).
RN   [17]
RP   FUNCTION.
RX   PubMed=11112772; DOI=10.1074/jbc.M006130200;
RA   Ping Y.-H., Rana T.M.;
RT   "DSIF and NELF interact with RNA polymerase II elongation complex and
RT   HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase
RT   II and DSIF during transcription elongation.";
RL   J. Biol. Chem. 276:12951-12958(2001).
RN   [18]
RP   FUNCTION.
RX   PubMed=11575923; DOI=10.1006/jmbi.2001.4991;
RA   Lavoie S.B., Albert A.L., Handa H., Vincent M., Bensaude O.;
RT   "The peptidyl-prolyl isomerase Pin1 interacts with hSpt5
RT   phosphorylated by Cdk9.";
RL   J. Mol. Biol. 312:675-685(2001).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH CCNK/CYCLIN K.
RX   PubMed=11884399; DOI=10.1074/jbc.M200117200;
RA   Lin X., Taube R., Fujinaga K., Peterlin B.M.;
RT   "P-TEFb containing cyclin K and Cdk9 can activate transcription via
RT   RNA.";
RL   J. Biol. Chem. 277:16873-16878(2002).
RN   [20]
RP   INTERACTION WITH AFF4.
RX   PubMed=12065898; DOI=10.1007/BF02256070;
RA   Estable M.C., Naghavi M.H., Kato H., Xiao H., Qin J., Vahlne A.,
RA   Roeder R.G.;
RT   "MCEF, the newest member of the AF4 family of transcription factors
RT   involved in leukemia, is a positive transcription elongation factor-b-
RT   associated protein.";
RL   J. Biomed. Sci. 9:234-245(2002).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12115727; DOI=10.1002/jcp.10130;
RA   Napolitano G., Licciardo P., Carbone R., Majello B., Lania L.;
RT   "CDK9 has the intrinsic property to shuttle between nucleus and
RT   cytoplasm, and enhanced expression of cyclin T1 promotes its nuclear
RT   localization.";
RL   J. Cell. Physiol. 192:209-215(2002).
RN   [22]
RP   FUNCTION.
RX   PubMed=11809800; DOI=10.1128/MCB.22.4.1079-1093.2002;
RA   Bourgeois C.F., Kim Y.K., Churcher M.J., West M.J., Karn J.;
RT   "Spt5 cooperates with human immunodeficiency virus type 1 Tat by
RT   preventing premature RNA release at terminator sequences.";
RL   Mol. Cell. Biol. 22:1079-1093(2002).
RN   [23]
RP   FUNCTION AS MYOD1 KINASE, AND INTERACTION WITH MYOD1 AND CCNT2.
RX   PubMed=12037670; DOI=10.1038/sj.onc.1205493;
RA   Simone C., Stiegler P., Bagella L., Pucci B., Bellan C., De Falco G.,
RA   De Luca A., Guanti G., Puri P.L., Giordano A.;
RT   "Activation of MyoD-dependent transcription by cdk9/cyclin T2.";
RL   Oncogene 21:4137-4148(2002).
RN   [24]
RP   INTERACTION WITH SUPT5H.
RX   PubMed=12718890; DOI=10.1016/S1097-2765(03)00101-1;
RA   Kwak Y.T., Guo J., Prajapati S., Park K.-J., Surabhi R.M., Miller B.,
RA   Gehrig P., Gaynor R.B.;
RT   "Methylation of SPT5 regulates its interaction with RNA polymerase II
RT   and transcriptional elongation properties.";
RL   Mol. Cell 11:1055-1066(2003).
RN   [25]
RP   FUNCTION.
RX   PubMed=15564463; DOI=10.1128/JVI.78.24.13522-13533.2004;
RA   Zhou M., Deng L., Lacoste V., Park H.U., Pumfery A., Kashanchi F.,
RA   Brady J.N., Kumar A.;
RT   "Coordination of transcription factor phosphorylation and histone
RT   methylation by the P-TEFb kinase during human immunodeficiency virus
RT   type 1 transcription.";
RL   J. Virol. 78:13522-13533(2004).
RN   [26]
RP   FUNCTION.
RX   PubMed=14701750; DOI=10.1128/MCB.24.2.787-795.2004;
RA   Fujinaga K., Irwin D., Huang Y., Taube R., Kurosu T., Peterlin B.M.;
RT   "Dynamics of human immunodeficiency virus transcription: P-TEFb
RT   phosphorylates RD and dissociates negative effectors from the
RT   transactivation response element.";
RL   Mol. Cell. Biol. 24:787-795(2004).
RN   [27]
RP   IDENTIFICATION IN INACTIVE 7SK SNRNP COMPLEX, AND PHOSPHORYLATION AT
RP   THR-186.
RX   PubMed=15965233; DOI=10.1074/jbc.M502712200;
RA   Li Q., Price J.P., Byers S.A., Cheng D., Peng J., Price D.H.;
RT   "Analysis of the large inactive P-TEFb complex indicates that it
RT   contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb
RT   molecules containing Cdk9 phosphorylated at threonine 186.";
RL   J. Biol. Chem. 280:28819-28826(2005).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH BRD4.
RX   PubMed=16109376; DOI=10.1016/j.molcel.2005.06.027;
RA   Jang M.K., Mochizuki K., Zhou M., Jeong H.S., Brady J.N., Ozato K.;
RT   "The bromodomain protein Brd4 is a positive regulatory component of P-
RT   TEFb and stimulates RNA polymerase II-dependent transcription.";
RL   Mol. Cell 19:523-534(2005).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH BRD4.
RX   PubMed=16109377; DOI=10.1016/j.molcel.2005.06.029;
RA   Yang Z., Yik J.H., Chen R., He N., Jang M.K., Ozato K., Zhou Q.;
RT   "Recruitment of P-TEFb for stimulation of transcriptional elongation
RT   by the bromodomain protein Brd4.";
RL   Mol. Cell 19:535-545(2005).
RN   [30]
RP   FUNCTION IN CYTOKINE SIGNALING, AND INTERACTION WITH STAT3.
RX   PubMed=17956865; DOI=10.1074/jbc.M706458200;
RA   Hou T., Ray S., Brasier A.R.;
RT   "The functional role of an interleukin 6-inducible CDK9.STAT3 complex
RT   in human gamma-fibrinogen gene expression.";
RL   J. Biol. Chem. 282:37091-37102(2007).
RN   [31]
RP   IDENTIFICATION IN THE 7SK SNRNP COMPLEX.
RX   PubMed=17643375; DOI=10.1016/j.molcel.2007.06.027;
RA   Jeronimo C., Forget D., Bouchard A., Li Q., Chua G., Poitras C.,
RA   Therien C., Bergeron D., Bourassa S., Greenblatt J., Chabot B.,
RA   Poirier G.G., Hughes T.R., Blanchette M., Price D.H., Coulombe B.;
RT   "Systematic analysis of the protein interaction network for the human
RT   transcription machinery reveals the identity of the 7SK capping
RT   enzyme.";
RL   Mol. Cell 27:262-274(2007).
RN   [32]
RP   ACETYLATION AT LYS-44 BY P300/CBP, IDENTIFICATION IN COMPLEX WITH
RP   NCOR1; HEXIM1 AND HDAC3, AND MUTAGENESIS OF LYS-44.
RX   PubMed=17452463; DOI=10.1128/MCB.00857-06;
RA   Fu J., Yoon H.-G., Qin J., Wong J.;
RT   "Regulation of P-TEFb elongation complex activity by CDK9
RT   acetylation.";
RL   Mol. Cell. Biol. 27:4641-4651(2007).
RN   [33]
RP   PHOSPHORYLATION AT THR-186, DEPHOSPHORYLATION BY PPP1CA, P-TEFB/7SK
RP   SNRNP COMPLEX, SUBUNIT, INTERACTION WITH BRD4, AND ENZYME REGULATION.
RX   PubMed=18483222; DOI=10.1101/gad.1636008;
RA   Chen R., Liu M., Li H., Xue Y., Ramey W.N., He N., Ai N., Luo H.,
RA   Zhu Y., Zhou N., Zhou Q.;
RT   "PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb
RT   for transcription in response to Ca2+ signaling.";
RL   Genes Dev. 22:1356-1368(2008).
RN   [34]
RP   PHOSPHORYLATION AT THR-186, AND DEPHOSPHORYLATION BY PPM1A AND PPM1B.
RX   PubMed=18829461; DOI=10.1074/jbc.M807495200;
RA   Wang Y., Dow E.C., Liang Y.Y., Ramakrishnan R., Liu H., Sung T.L.,
RA   Lin X., Rice A.P.;
RT   "Phosphatase PPM1A regulates phosphorylation of Thr-186 in the Cdk9 T-
RT   loop.";
RL   J. Biol. Chem. 283:33578-33584(2008).
RN   [35]
RP   IDENTIFICATION IN COMPLEX WITH LARP7 IN 7SK SNRNP COMPLEX.
RX   PubMed=18249148; DOI=10.1016/j.molcel.2008.01.003;
RA   He N., Jahchan N.S., Hong E., Li Q., Bayfield M.A., Maraia R.J.,
RA   Luo K., Zhou Q.;
RT   "A La-related protein modulates 7SK snRNP integrity to suppress P-
RT   TEFb-dependent transcriptional elongation and tumorigenesis.";
RL   Mol. Cell 29:588-599(2008).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT SER-35 (ISOFORM 2), AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [37]
RP   ACETYLATION AT LYS-44 AND LYS-48 BY PCAF/KAT2B AND GCN5/KAT2A, ENZYME
RP   REGULATION BY ACETYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18250157; DOI=10.1128/MCB.01557-07;
RA   Sabo A., Lusic M., Cereseto A., Giacca M.;
RT   "Acetylation of conserved lysines in the catalytic core of cyclin-
RT   dependent kinase 9 inhibits kinase activity and regulates
RT   transcription.";
RL   Mol. Cell. Biol. 28:2201-2212(2008).
RN   [38]
RP   FUNCTION IN CYTOKINE SIGNALING, AND INTERACTION WITH RELA/P65.
RX   PubMed=18362169; DOI=10.1128/MCB.01152-07;
RA   Nowak D.E., Tian B., Jamaluddin M., Boldogh I., Vergara L.A.,
RA   Choudhary S., Brasier A.R.;
RT   "RelA Ser276 phosphorylation is required for activation of a subset of
RT   NF-kappaB-dependent genes by recruiting cyclin-dependent kinase
RT   9/cyclin T1 complexes.";
RL   Mol. Cell. Biol. 28:3623-3638(2008).
RN   [39]
RP   FUNCTION IN HISTONE REGULATION.
RX   PubMed=19844166; DOI=10.4161/cc.8.22.9890;
RA   Pirngruber J., Shchebet A., Johnsen S.A.;
RT   "Insights into the function of the human P-TEFb component CDK9 in the
RT   regulation of chromatin modifications and co-transcriptional mRNA
RT   processing.";
RL   Cell Cycle 8:3636-3642(2009).
RN   [40]
RP   FUNCTION IN HISTONE H2B UBIQUITINATION.
RX   PubMed=19575011; DOI=10.1038/embor.2009.108;
RA   Pirngruber J., Shchebet A., Schreiber L., Shema E., Minsky N.,
RA   Chapman R.D., Eick D., Aylon Y., Oren M., Johnsen S.A.;
RT   "CDK9 directs H2B monoubiquitination and controls replication-
RT   dependent histone mRNA 3'-end processing.";
RL   EMBO Rep. 10:894-900(2009).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347 AND THR-350,
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35 (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [42]
RP   FUNCTION IN DNA REPAIR, AND INTERACTION WITH KU70/XRCC6.
RX   PubMed=20493174; DOI=10.1016/j.bbrc.2010.05.092;
RA   Liu H., Herrmann C.H., Chiang K., Sung T.L., Moon S.H.,
RA   Donehower L.A., Rice A.P.;
RT   "55K isoform of CDK9 associates with Ku70 and is involved in DNA
RT   repair.";
RL   Biochem. Biophys. Res. Commun. 397:245-250(2010).
RN   [43]
RP   FUNCTION IN CDK9/CYCLIN K COMPLEX DURING REPLICATION STRESS.
RX   PubMed=20930849; DOI=10.1038/embor.2010.153;
RA   Yu D.S., Zhao R., Hsu E.L., Cayer J., Ye F., Guo Y., Shyr Y.,
RA   Cortez D.;
RT   "Cyclin-dependent kinase 9-cyclin K functions in the replication
RT   stress response.";
RL   EMBO Rep. 11:876-882(2010).
RN   [44]
RP   FUNCTION IN CARDIAC HYPERTROPHY, AND IDENTIFICATION IN COMPLEX WITH
RP   CCNT1/CYCLIN-T1; EP300 AND GATA4.
RX   PubMed=20081228; DOI=10.1074/jbc.M109.070458;
RA   Sunagawa Y., Morimoto T., Takaya T., Kaichi S., Wada H., Kawamura T.,
RA   Fujita M., Shimatsu A., Kita T., Hasegawa K.;
RT   "Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex
RT   required for phenylephrine-induced hypertrophy in cardiomyocytes.";
RL   J. Biol. Chem. 285:9556-9568(2010).
RN   [45]
RP   IDENTIFICATION IN THE SEC COMPLEX.
RX   PubMed=20471948; DOI=10.1016/j.molcel.2010.04.013;
RA   He N., Liu M., Hsu J., Xue Y., Chou S., Burlingame A., Krogan N.J.,
RA   Alber T., Zhou Q.;
RT   "HIV-1 Tat and host AFF4 recruit two transcription elongation factors
RT   into a bifunctional complex for coordinated activation of HIV-1
RT   transcription.";
RL   Mol. Cell 38:428-438(2010).
RN   [46]
RP   IDENTIFICATION IN THE SEC COMPLEX.
RX   PubMed=20159561; DOI=10.1016/j.molcel.2010.01.026;
RA   Lin C., Smith E.R., Takahashi H., Lai K.C., Martin-Brown S.,
RA   Florens L., Washburn M.P., Conaway J.W., Conaway R.C., Shilatifard A.;
RT   "AFF4, a component of the ELL/P-TEFb elongation complex and a shared
RT   subunit of MLL chimeras, can link transcription elongation to
RT   leukemia.";
RL   Mol. Cell 37:429-437(2010).
RN   [47]
RP   FUNCTION IN AR KINASE, AND INTERACTION WITH AR.
RX   PubMed=20980437; DOI=10.1210/me.2010-0238;
RA   Gordon V., Bhadel S., Wunderlich W., Zhang J., Ficarro S.B.,
RA   Mollah S.A., Shabanowitz J., Hunt D.F., Xenarios I., Hahn W.C.,
RA   Conaway M., Carey M.F., Gioeli D.;
RT   "CDK9 regulates AR promoter selectivity and cell growth through serine
RT   81 phosphorylation.";
RL   Mol. Endocrinol. 24:2267-2280(2010).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [49]
RP   IDENTIFICATION IN THE SEC COMPLEX.
RX   PubMed=22195968; DOI=10.1016/j.molcel.2011.12.008;
RA   Smith E.R., Lin C., Garrett A.S., Thornton J., Mohaghegh N., Hu D.,
RA   Jackson J., Saraf A., Swanson S.K., Seidel C., Florens L.,
RA   Washburn M.P., Eissenberg J.C., Shilatifard A.;
RT   "The little elongation complex regulates small nuclear RNA
RT   transcription.";
RL   Mol. Cell 44:954-965(2011).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-186, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [51]
RP   ENZYME REGULATION BY CDKI-71.
RX   PubMed=21484792; DOI=10.1002/ijc.26127;
RA   Liu X., Shi S., Lam F., Pepper C., Fischer P.M., Wang S.;
RT   "CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to
RT   cancer cells compared to flavopiridol.";
RL   Int. J. Cancer 130:1216-1226(2012).
RN   [52]
RP   FUNCTION AS RPB1/POLR2A CTD KINASE, POLYUBIQUITINATION BY UBR5, AND
RP   INTERACTION WITH UBR5 AND TFIIS/TCEA1.
RX   PubMed=21127351; DOI=10.1074/jbc.M110.176628;
RA   Cojocaru M., Bouchard A., Cloutier P., Cooper J.J., Varzavand K.,
RA   Price D.H., Coulombe B.;
RT   "Transcription factor IIS cooperates with the E3 ligase UBR5 to
RT   ubiquitinate the CDK9 subunit of the positive transcription elongation
RT   factor B.";
RL   J. Biol. Chem. 286:5012-5022(2011).
RN   [53]
RP   PHOSPHORYLATION AT THR-186, ENZYME REGULATION, DEGRADATION BY THE
RP   PROTEASOME, AND MUTAGENESIS OF THR-186.
RX   PubMed=21448926; DOI=10.1002/jcp.22760;
RA   Ramakrishnan R., Rice A.P.;
RT   "Cdk9 T-loop phosphorylation is regulated by the calcium signaling
RT   pathway.";
RL   J. Cell. Physiol. 227:609-617(2012).
RN   [54]
RP   PHOSPHORYLATION AT SER-175, DEPHOSPHORYLATION AT SER-175 BY PP1, AND
RP   MUTAGENESIS OF SER-175.
RX   PubMed=21533037; DOI=10.1371/journal.pone.0018985;
RA   Ammosova T., Obukhov Y., Kotelkin A., Breuer D., Beullens M.,
RA   Gordeuk V.R., Bollen M., Nekhai S.;
RT   "Protein phosphatase-1 activates CDK9 by dephosphorylating Ser175.";
RL   PLoS ONE 6:E18985-E18985(2011).
RN   [55]
RP   REVIEW ON NELF AND DSIF KINASE ACTIVITY.
RX   PubMed=16885020; DOI=10.1016/j.molcel.2006.06.014;
RA   Peterlin B.M., Price D.H.;
RT   "Controlling the elongation phase of transcription with P-TEFb.";
RL   Mol. Cell 23:297-305(2006).
RN   [56]
RP   REVIEW ON CYTOKINE SIGNALING.
RX   PubMed=18728388; DOI=10.4161/cc.7.17.6594;
RA   Brasier A.R.;
RT   "Expanding role of cyclin dependent kinases in cytokine inducible gene
RT   expression.";
RL   Cell Cycle 7:2661-2666(2008).
RN   [57]
RP   REVIEW ON TRANSCRIPTION REGULATION, AND INHIBITORS.
RX   PubMed=19029809; DOI=10.4161/cc.7.23.7122;
RA   Romano G., Giordano A.;
RT   "Role of the cyclin-dependent kinase 9-related pathway in mammalian
RT   gene expression and human diseases.";
RL   Cell Cycle 7:3664-3668(2008).
RN   [58]
RP   REVIEW ON TRANSCRIPTION REGULATION, AND INHIBITORS.
RX   PubMed=18423896; DOI=10.1016/j.tips.2008.03.003;
RA   Wang S., Fischer P.M.;
RT   "Cyclin-dependent kinase 9: a key transcriptional regulator and
RT   potential drug target in oncology, virology and cardiology.";
RL   Trends Pharmacol. Sci. 29:302-313(2008).
RN   [59]
RP   ENZYME REGULATION, AND GENE FAMILY.
RX   PubMed=19238148; DOI=10.1038/nrc2602;
RA   Malumbres M., Barbacid M.;
RT   "Cell cycle, CDKs and cancer: a changing paradigm.";
RL   Nat. Rev. Cancer 9:153-166(2009).
RN   [60]
RP   REVIEW ON CARDIAC HYPERTROPHY, AND INHIBITORS.
RX   PubMed=19757441; DOI=10.1002/med.20172;
RA   Krystof V., Chamrad I., Jorda R., Kohoutek J.;
RT   "Pharmacological targeting of CDK9 in cardiac hypertrophy.";
RL   Med. Res. Rev. 30:646-666(2010).
RN   [61]
RP   REVIEW ON GENOME INTEGRITY MAINTENANCE.
RX   PubMed=21200140; DOI=10.4161/cc.10.1.14364;
RA   Yu D.S., Cortez D.;
RT   "A role for cdk9-cyclin k in maintaining genome integrity.";
RL   Cell Cycle 10:28-32(2011).
RN   [62]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 PROTEIN ICP22.
RX   PubMed=23029222; DOI=10.1371/journal.pone.0045749;
RA   Guo L., Wu W.J., Liu L.D., Wang L.C., Zhang Y., Wu L.Q., Guan Y.,
RA   Li Q.H.;
RT   "Herpes simplex virus 1 ICP22 inhibits the transcription of viral gene
RT   promoters by binding to and blocking the recruitment of P-TEFb.";
RL   PLoS ONE 7:E45749-E45749(2012).
RN   [63]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-347, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT THR-54 (ISOFORM 2), AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [64]
RP   INTERACTION WITH HSF1.
RX   PubMed=27189267; DOI=10.1038/srep26294;
RA   Pan X.Y., Zhao W., Zeng X.Y., Lin J., Li M.M., Shen X.T., Liu S.W.;
RT   "Heat shock factor 1 mediates latent HIV reactivation.";
RL   Sci. Rep. 6:26294-26294(2016).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1-345 IN COMPLEX WITH HIV-1
RP   TAT AND CCNT1, AND PHOSPHORYLATION AT THR-186.
RX   PubMed=20535204; DOI=10.1038/nature09131;
RA   Tahirov T.H., Babayeva N.D., Varzavand K., Cooper J.J., Sedore S.C.,
RA   Price D.H.;
RT   "Crystal structure of HIV-1 Tat complexed with human P-TEFb.";
RL   Nature 465:747-751(2010).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (2.48 ANGSTROMS) OF 2-330 IN COMPLEX WITH
RP   INHIBITOR FLAVOPIRIDOL; ATP AND CCNT1, PHOSPHORYLATION AT THR-186
RP   SER-347; THR-362 AND THR-363, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   THR-186.
RX   PubMed=18566585; DOI=10.1038/emboj.2008.121;
RA   Baumli S., Lolli G., Lowe E.D., Troiani S., Rusconi L., Bullock A.N.,
RA   Debreczeni J.E., Knapp S., Johnson L.N.;
RT   "The structure of P-TEFb (CDK9/cyclin T1), its complex with
RT   flavopiridol and regulation by phosphorylation.";
RL   EMBO J. 27:1907-1918(2008).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 2-330 IN COMPLEX WITH
RP   INHIBITOR DRB, AND PHOSPHORYLATION AT THR-186.
RX   PubMed=20851342; DOI=10.1016/j.chembiol.2010.07.012;
RA   Baumli S., Endicott J.A., Johnson L.N.;
RT   "Halogen bonds form the basis for selective P-TEFb inhibition by
RT   DRB.";
RL   Chem. Biol. 17:931-936(2010).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 2-330 IN COMPLEX WITH CCNT1;
RP   INHIBITORS ROSCOVITINE AND CR8, PHOSPHORYLATION AT THR-186, AND ENZYME
RP   REGULATION.
RX   PubMed=21779453; DOI=10.1177/1947601910369817;
RA   Bettayeb K., Baunbaek D., Delehouze C., Loaec N., Hole A.J.,
RA   Baumli S., Endicott J.A., Douc-Rasy S., Benard J., Oumata N.,
RA   Galons H., Meijer L.;
RT   "CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and
RT   apoptotic cell death in neuroblastoma cells.";
RL   Genes Cancer 1:369-380(2010).
RN   [69]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-59.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase involved in the regulation of
CC       transcription. Member of the cyclin-dependent kinase pair
CC       (CDK9/cyclin-T) complex, also called positive transcription
CC       elongation factor b (P-TEFb), which facilitates the transition
CC       from abortive to productive elongation by phosphorylating the CTD
CC       (C-terminal domain) of the large subunit of RNA polymerase II
CC       (RNAP II) POLR2A, SUPT5H and RDBP. This complex is inactive when
CC       in the 7SK snRNP complex form. Phosphorylates EP300, MYOD1,
CC       RPB1/POLR2A and AR, and the negative elongation factors DSIF and
CC       NELF. Regulates cytokine inducible transcription networks by
CC       facilitating promoter recognition of target transcription factors
CC       (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3
CC       signaling). Promotes RNA synthesis in genetic programs for cell
CC       growth, differentiation and viral pathogenesis. P-TEFb is also
CC       involved in cotranscriptional histone modification, mRNA
CC       processing and mRNA export. Modulates a complex network of
CC       chromatin modifications including histone H2B monoubiquitination
CC       (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3;
CC       integrates phosphorylation during transcription with chromatin
CC       modifications to control co-transcriptional histone mRNA
CC       processing. The CDK9/cyclin-K complex has also a kinase activity
CC       towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb
CC       in vitro. Replication stress response protein; the CDK9/cyclin-K
CC       complex is required for genome integrity maintenance, by promoting
CC       cell cycle recovery from replication arrest and limiting single-
CC       stranded DNA amount in response to replication stress, thus
CC       reducing the breakdown of stalled replication forks and avoiding
CC       DNA damage. In addition, probable function in DNA repair of
CC       isoform 2 via interaction with KU70/XRCC6. Promotes cardiac
CC       myocyte enlargement. RPB1/POLR2A phosphorylation on 'Ser-2' in CTD
CC       activates transcription. AR phosphorylation modulates AR
CC       transcription factor promoter selectivity and cell growth. DSIF
CC       and NELF phosphorylation promotes transcription by inhibiting
CC       their negative effect. The phosphorylation of MYOD1 enhances its
CC       transcriptional activity and thus promotes muscle differentiation.
CC       {ECO:0000269|PubMed:10393184, ECO:0000269|PubMed:10574912,
CC       ECO:0000269|PubMed:10757782, ECO:0000269|PubMed:10912001,
CC       ECO:0000269|PubMed:11112772, ECO:0000269|PubMed:11145967,
CC       ECO:0000269|PubMed:11575923, ECO:0000269|PubMed:11809800,
CC       ECO:0000269|PubMed:11884399, ECO:0000269|PubMed:12037670,
CC       ECO:0000269|PubMed:14701750, ECO:0000269|PubMed:15564463,
CC       ECO:0000269|PubMed:16109376, ECO:0000269|PubMed:16109377,
CC       ECO:0000269|PubMed:17956865, ECO:0000269|PubMed:18362169,
CC       ECO:0000269|PubMed:19575011, ECO:0000269|PubMed:19844166,
CC       ECO:0000269|PubMed:20081228, ECO:0000269|PubMed:20493174,
CC       ECO:0000269|PubMed:20930849, ECO:0000269|PubMed:20980437,
CC       ECO:0000269|PubMed:21127351, ECO:0000269|PubMed:9857195}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: ATP + [DNA-directed RNA polymerase] = ADP +
CC       [DNA-directed RNA polymerase] phosphate.
CC   -!- ENZYME REGULATION: Inhibited by CDKI-71, CR8, GPC-286199, AG-
CC       024322, flavopiridol (alvocidib), RBG-286147, anilinopyrimidine
CC       32, arylazopyrazole 31b, indirubin 3'-monoxime, meriolin 3,P276-
CC       00, olomoucine II, pyrazolotriazine, meriolin, variolin,
CC       thiazolyl-pyrimidine, thiazolyl-pyrimidine, indirubin-30-monoxime,
CC       ZK 304709, AG-012986, AT7519, R547, RGB-286638, imidazole
CC       pyrimidine, EXEL-3700, EXEL-8647, 5,6-dichloro-1-b-ribofur-anosyl-
CC       benzimidazole (DRB), P276-00, roscovitine (seliciclib, CYC202) and
CC       SNS-032 (BMS-387032). Activation by Thr-186 phosphorylation is
CC       calcium Ca(2+) signaling pathway-dependent; actively inactivated
CC       by dephosphorylation mediated by PPP1CA, PPM1A and PPM1B.
CC       Reversibly repressed by acetylation at Lys-44 and Lys-48.
CC       {ECO:0000269|PubMed:18250157, ECO:0000269|PubMed:18483222,
CC       ECO:0000269|PubMed:19238148, ECO:0000269|PubMed:21448926,
CC       ECO:0000269|PubMed:21484792, ECO:0000269|PubMed:21779453}.
CC   -!- SUBUNIT: Component of the super elongation complex (SEC), at least
CC       composed of EAF1, EAF2, CDK9, MLLT3/AF9, AFF (AFF1 or AFF4), the
CC       P-TEFb complex and ELL (ELL, ELL2 or ELL3). Associates with
CC       CCNT1/cyclin-T1, CCNT2/cyclin-T2 (isoform A and isoform B) or
CC       CCNK/cyclin-K to form active P-TEFb. P-TEFb forms a complex with
CC       AFF4/AF5Q31 and is part of the super elongation complex (SEC).
CC       Component of a complex which is composed of at least 5 members:
CC       HTATSF1/Tat-SF1, P-TEFb complex, RNA pol II, SUPT5H, and
CC       NCL/nucleolin. Associates with UBR5 and forms a transcription
CC       regulatory complex composed of CDK9, RNAP II, UBR5 and TFIIS/TCEA1
CC       that can stimulate target gene transcription (e.g. gamma
CC       fibrinogen/FGG) by recruiting their promoters. Component of the
CC       7SK snRNP inactive complex which is composed of at least 8
CC       members: P-TEFb (composed of CDK9 and CCNT1/cyclin-T1), HEXIM1,
CC       HEXIM2, LARP7, BCDIN3, SART3 proteins and 7SK and U6 snRNAs. This
CC       inactive 7SK snRNP complex can also interact with NCOR1 and HDAC3,
CC       probably to regulate CDK9 acetylation. Release of P-TEFb from P-
CC       TEFb/7SK snRNP complex requires both PP2B to transduce calcium
CC       Ca(2+) signaling in response to stimuli (e.g. UV or hexamethylene
CC       bisacetamide (HMBA)), and PPP1CA to dephosphorylate Thr-186. This
CC       released P-TEFb remains inactive in the pre-initiation complex
CC       with BRD4 until new Thr-186 phosphorylation occurs after the
CC       synthesis of a short RNA. Interacts with BRD4, probably to target
CC       chromatin binding. Interacts with the acidic/proline-rich region
CC       of HIV-1 and HIV-2 Tat via T-loop region, and is thus required for
CC       HIV to hijack host transcription machinery during its replication
CC       through cooperative binding to viral TAR RNA. Interacts with
CC       activated nuclear STAT3 and RELA/p65. Binds to AR and MYOD1. Forms
CC       a complex composed of CDK9, CCNT1/cyclin-T1, EP300 and GATA4 that
CC       stimulates hypertrophy in cardiomyocytes. The large PER complex
CC       involved in the repression of transcriptional termination is
CC       composed of at least PER2, CDK9, DDX5, DHX9, NCBP1 and POLR2A.
CC       Isoform 3 binds to KU70/XRCC6. Interacts with herpes simplex virus
CC       1 protein ICP22; this interaction inhibits the positive
CC       transcription elongation factor b (P-TEFb). Interacts with HSF1
CC       (PubMed:27189267). {ECO:0000269|PubMed:10393184,
CC       ECO:0000269|PubMed:10574912, ECO:0000269|PubMed:10958691,
CC       ECO:0000269|PubMed:11884399, ECO:0000269|PubMed:12037670,
CC       ECO:0000269|PubMed:12065898, ECO:0000269|PubMed:12718890,
CC       ECO:0000269|PubMed:15965233, ECO:0000269|PubMed:16109376,
CC       ECO:0000269|PubMed:16109377, ECO:0000269|PubMed:17452463,
CC       ECO:0000269|PubMed:17643375, ECO:0000269|PubMed:17956865,
CC       ECO:0000269|PubMed:18249148, ECO:0000269|PubMed:18362169,
CC       ECO:0000269|PubMed:18483222, ECO:0000269|PubMed:18566585,
CC       ECO:0000269|PubMed:20081228, ECO:0000269|PubMed:20159561,
CC       ECO:0000269|PubMed:20471948, ECO:0000269|PubMed:20493174,
CC       ECO:0000269|PubMed:20535204, ECO:0000269|PubMed:20851342,
CC       ECO:0000269|PubMed:20980437, ECO:0000269|PubMed:21127351,
CC       ECO:0000269|PubMed:21779453, ECO:0000269|PubMed:22195968,
CC       ECO:0000269|PubMed:23029222, ECO:0000269|PubMed:27189267,
CC       ECO:0000269|PubMed:9491887, ECO:0000269|PubMed:9499409}.
CC   -!- INTERACTION:
CC       Q13535:ATR; NbExp=3; IntAct=EBI-1383449, EBI-968983;
CC       Q8WXE1:ATRIP; NbExp=3; IntAct=EBI-1383449, EBI-747353;
CC       O60563:CCNT1; NbExp=13; IntAct=EBI-1383449, EBI-2479671;
CC       Q16543:CDC37; NbExp=3; IntAct=EBI-1383449, EBI-295634;
CC       Q9HAW4:CLSPN; NbExp=3; IntAct=EBI-1383449, EBI-1369377;
CC       Q7L2E3:DHX30; NbExp=5; IntAct=EBI-1383449, EBI-1211456;
CC       Q13451:FKBP5; NbExp=4; IntAct=EBI-1383449, EBI-306914;
CC       O94992:HEXIM1; NbExp=7; IntAct=EBI-1383449, EBI-2832510;
CC       P07900:HSP90AA1; NbExp=2; IntAct=EBI-1383449, EBI-296047;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-1383449, EBI-352572;
CC       Q6NYC1:JMJD6; NbExp=5; IntAct=EBI-1383449, EBI-8464037;
CC       Q4G0J3:LARP7; NbExp=7; IntAct=EBI-1383449, EBI-2371923;
CC       Q9Y5X4:NR2E3; NbExp=4; IntAct=EBI-1383449, EBI-7216962;
CC       P04608:tat (xeno); NbExp=5; IntAct=EBI-1383449, EBI-6164389;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Nucleus, PML body.
CC       Note=Accumulates on chromatin in response to replication stress.
CC       Complexed with CCNT1 in nuclear speckles, but uncomplexed form in
CC       the cytoplasm. The translocation from nucleus to cytoplasm is
CC       XPO1/CRM1-dependent. Associates with PML body when acetylated.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P50750-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P50750-2; Sequence=VSP_016288;
CC         Note=Contains a phosphoserine at position 35. Contains a
CC         phosphothreonine at position 54. {ECO:0000244|PubMed:18691976,
CC         ECO:0000244|PubMed:19369195, ECO:0000244|PubMed:24275569};
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- INDUCTION: By replication stress, in chromatin. Probably degraded
CC       by the proteasome upon Thr-186 dephosphorylation.
CC   -!- PTM: Autophosphorylation at Thr-186, Ser-347, Thr-350, Ser-353,
CC       Thr-354 and Ser-357 triggers kinase activity by promoting cyclin
CC       and substrate binding (e.g. HIV TAT) upon conformational changes.
CC       Thr-186 phosphorylation requires the calcium Ca(2+) signaling
CC       pathway, including CaMK1D and calmodulin. This inhibition is
CC       relieved by Thr-29 dephosphorylation. However, phosphorylation at
CC       Thr-29 is inhibitory within the HIV transcription initiation
CC       complex. Phosphorylation at Ser-175 inhibits kinase activity. Can
CC       be phosphorylated on either Thr-362 or Thr-363 but not on both
CC       simultaneously (PubMed:18566585). {ECO:0000269|PubMed:10958691,
CC       ECO:0000269|PubMed:15965233, ECO:0000269|PubMed:18483222,
CC       ECO:0000269|PubMed:18566585, ECO:0000269|PubMed:18829461,
CC       ECO:0000269|PubMed:20535204, ECO:0000269|PubMed:20851342,
CC       ECO:0000269|PubMed:21448926, ECO:0000269|PubMed:21533037,
CC       ECO:0000269|PubMed:21779453}.
CC   -!- PTM: Dephosphorylation of Thr-186 by PPM1A and PPM1B blocks CDK9
CC       activity and may lead to CDK9 proteasomal degradation. However,
CC       PPP1CA-mediated Thr-186 dephosphorylation is required to release
CC       P-TEFb from its inactive P-TEFb/7SK snRNP complex.
CC       Dephosphorylation of C-terminus Thr and Ser residues by protein
CC       phosphatase-1 (PP1) triggers CDK9 activity, contributing to the
CC       activation of HIV-1 transcription.
CC   -!- PTM: N6-acetylation of Lys-44 by CBP/p300 promotes kinase
CC       activity, whereas acetylation of both Lys-44 and Lys-48 mediated
CC       by PCAF/KAT2B and GCN5/KAT2A reduces kinase activity. The
CC       acetylated form associates with PML bodies in the nuclear matrix
CC       and with the transcriptionally silent HIV-1 genome; deacetylated
CC       upon transcription stimulation. {ECO:0000269|PubMed:17452463,
CC       ECO:0000269|PubMed:18250157}.
CC   -!- PTM: Polyubiquitinated and thus activated by UBR5. This
CC       ubiquitination is promoted by TFIIS/TCEA1 and favors 'Ser-2'
CC       phosphorylation of RPB1/POLR2A CTD. {ECO:0000269|PubMed:21127351}.
CC   -!- DISEASE: Note=Chronic activation of CDK9 causes cardiac myocyte
CC       enlargement leading to cardiac hypertrophy, and confers
CC       predisposition to heart failure.
CC   -!- MISCELLANEOUS: CDK9 inhibition contributes to the anticancer
CC       activity of most CDK inhibitors under clinical investigation
CC       (PubMed:18423896 and PubMed:21779453). As a retroviruses target
CC       during the hijack of host transcription (e.g. HIV), CDK9
CC       inhibitors might become specific antiretroviral agents
CC       (PubMed:18423896). May be a target for cardiac hypertrophy future
CC       treatments (PubMed:19757441 and PubMed:18423896). May also be a
CC       target in anti-inflammatory therapy in innate immunity and
CC       systemic inflammation (PubMed:18728388).
CC       {ECO:0000305|PubMed:18423896, ECO:0000305|PubMed:18728388}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAI39767.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdk9/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L25676; AAA35668.1; -; mRNA.
DR   EMBL; X80230; CAA56516.1; -; mRNA.
DR   EMBL; AF255306; AAF72183.1; -; Genomic_DNA.
DR   EMBL; BT019903; AAV38706.1; -; mRNA.
DR   EMBL; AF517840; AAM54039.1; -; Genomic_DNA.
DR   EMBL; AL162586; CAI39767.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL162586; CAI39768.1; -; Genomic_DNA.
DR   EMBL; BC001968; AAH01968.1; -; mRNA.
DR   CCDS; CCDS6879.1; -. [P50750-1]
DR   PIR; A55262; A55262.
DR   RefSeq; NP_001252.1; NM_001261.3. [P50750-1]
DR   UniGene; Hs.150423; -.
DR   UniGene; Hs.706809; -.
DR   PDB; 1PF6; Model; -; A=1-372.
DR   PDB; 3BLH; X-ray; 2.48 A; A=2-330.
DR   PDB; 3BLQ; X-ray; 2.90 A; A=2-330.
DR   PDB; 3BLR; X-ray; 2.80 A; A=2-330.
DR   PDB; 3LQ5; X-ray; 3.00 A; A=2-330.
DR   PDB; 3MI9; X-ray; 2.10 A; A=1-345.
DR   PDB; 3MIA; X-ray; 3.00 A; A=1-345.
DR   PDB; 3MY1; X-ray; 2.80 A; A=2-330.
DR   PDB; 3TN8; X-ray; 2.95 A; A=2-330.
DR   PDB; 3TNH; X-ray; 3.20 A; A=2-330.
DR   PDB; 3TNI; X-ray; 3.23 A; A=2-330.
DR   PDB; 4BCF; X-ray; 3.01 A; A=2-330.
DR   PDB; 4BCG; X-ray; 3.08 A; A=2-330.
DR   PDB; 4BCH; X-ray; 2.96 A; A=2-330.
DR   PDB; 4BCI; X-ray; 3.10 A; A=2-330.
DR   PDB; 4BCJ; X-ray; 3.16 A; A=2-330.
DR   PDB; 4EC8; X-ray; 3.60 A; A=2-372.
DR   PDB; 4EC9; X-ray; 3.21 A; A=2-372.
DR   PDB; 4IMY; X-ray; 2.94 A; A/C/E=1-330.
DR   PDB; 4OGR; X-ray; 3.00 A; A/E/I=1-330.
DR   PDB; 4OR5; X-ray; 2.90 A; A/F=7-332.
DR   PDB; 5L1Z; X-ray; 5.90 A; A=1-330.
DR   PDBsum; 1PF6; -.
DR   PDBsum; 3BLH; -.
DR   PDBsum; 3BLQ; -.
DR   PDBsum; 3BLR; -.
DR   PDBsum; 3LQ5; -.
DR   PDBsum; 3MI9; -.
DR   PDBsum; 3MIA; -.
DR   PDBsum; 3MY1; -.
DR   PDBsum; 3TN8; -.
DR   PDBsum; 3TNH; -.
DR   PDBsum; 3TNI; -.
DR   PDBsum; 4BCF; -.
DR   PDBsum; 4BCG; -.
DR   PDBsum; 4BCH; -.
DR   PDBsum; 4BCI; -.
DR   PDBsum; 4BCJ; -.
DR   PDBsum; 4EC8; -.
DR   PDBsum; 4EC9; -.
DR   PDBsum; 4IMY; -.
DR   PDBsum; 4OGR; -.
DR   PDBsum; 4OR5; -.
DR   PDBsum; 5L1Z; -.
DR   ProteinModelPortal; P50750; -.
DR   SMR; P50750; -.
DR   BioGrid; 107459; 190.
DR   DIP; DIP-29016N; -.
DR   IntAct; P50750; 70.
DR   MINT; MINT-1532814; -.
DR   STRING; 9606.ENSP00000362361; -.
DR   BindingDB; P50750; -.
DR   ChEMBL; CHEMBL3116; -.
DR   DrugBank; DB03496; Flavopiridol.
DR   GuidetoPHARMACOLOGY; 1981; -.
DR   iPTMnet; P50750; -.
DR   PhosphoSitePlus; P50750; -.
DR   BioMuta; CDK9; -.
DR   DMDM; 68067660; -.
DR   EPD; P50750; -.
DR   MaxQB; P50750; -.
DR   PaxDb; P50750; -.
DR   PeptideAtlas; P50750; -.
DR   PRIDE; P50750; -.
DR   DNASU; 1025; -.
DR   Ensembl; ENST00000373264; ENSP00000362361; ENSG00000136807. [P50750-1]
DR   GeneID; 1025; -.
DR   KEGG; hsa:1025; -.
DR   UCSC; uc004bse.3; human. [P50750-1]
DR   CTD; 1025; -.
DR   DisGeNET; 1025; -.
DR   GeneCards; CDK9; -.
DR   GeneCards; MIR2861; -.
DR   GeneCards; MIR3960; -.
DR   HGNC; HGNC:1780; CDK9.
DR   HPA; CAB004216; -.
DR   HPA; HPA006738; -.
DR   MIM; 603251; gene.
DR   neXtProt; NX_P50750; -.
DR   OpenTargets; ENSG00000136807; -.
DR   PharmGKB; PA26316; -.
DR   eggNOG; KOG0600; Eukaryota.
DR   eggNOG; ENOG410XPIR; LUCA.
DR   GeneTree; ENSGT00860000133755; -.
DR   HOGENOM; HOG000233024; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; P50750; -.
DR   KO; K02211; -.
DR   OMA; SITTEVW; -.
DR   OrthoDB; EOG091G08Z8; -.
DR   PhylomeDB; P50750; -.
DR   TreeFam; TF101039; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   BRENDA; 2.7.11.23; 2681.
DR   Reactome; R-HSA-112382; Formation of RNA Pol II elongation complex.
DR   Reactome; R-HSA-112387; Elongation arrest and recovery.
DR   Reactome; R-HSA-167152; Formation of HIV elongation complex in the absence of HIV Tat.
DR   Reactome; R-HSA-167200; Formation of HIV-1 elongation complex containing HIV-1 Tat.
DR   Reactome; R-HSA-167238; Pausing and recovery of Tat-mediated HIV elongation.
DR   Reactome; R-HSA-167243; Tat-mediated HIV elongation arrest and recovery.
DR   Reactome; R-HSA-167246; Tat-mediated elongation of the HIV-1 transcript.
DR   Reactome; R-HSA-167287; HIV elongation arrest and recovery.
DR   Reactome; R-HSA-167290; Pausing and recovery of HIV elongation.
DR   Reactome; R-HSA-176034; Interactions of Tat with host cellular proteins.
DR   Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6807505; RNA polymerase II transcribes snRNA genes.
DR   Reactome; R-HSA-75955; RNA Polymerase II Transcription Elongation.
DR   SignaLink; P50750; -.
DR   SIGNOR; P50750; -.
DR   ChiTaRS; CDK9; human.
DR   EvolutionaryTrace; P50750; -.
DR   GeneWiki; CDK9; -.
DR   GeneWiki; Cyclin-dependent_kinase_9; -.
DR   GenomeRNAi; 1025; -.
DR   PRO; PR:P50750; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000136807; -.
DR   CleanEx; HS_CDK9; -.
DR   ExpressionAtlas; P50750; baseline and differential.
DR   Genevisible; P50750; HS.
DR   GO; GO:0005694; C:chromosome; IBA:GO_Central.
DR   GO; GO:0008024; C:cyclin/CDK positive transcription elongation factor complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000932; C:P-body; IDA:HPA.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0008023; C:transcription elongation factor complex; IDA:UniProtKB.
DR   GO; GO:0097322; F:7SK snRNA binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0030332; F:cyclin binding; IBA:GO_Central.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0008353; F:RNA polymerase II carboxy-terminal domain kinase activity; IDA:UniProtKB.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IBA:GO_Central.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0071157; P:negative regulation of cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:1900364; P:negative regulation of mRNA polyadenylation; IMP:UniProtKB.
DR   GO; GO:0070816; P:phosphorylation of RNA polymerase II C-terminal domain; IBA:GO_Central.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IEA:Ensembl.
DR   GO; GO:2001168; P:positive regulation of histone H2B ubiquitination; IMP:UniProtKB.
DR   GO; GO:0033129; P:positive regulation of histone phosphorylation; IMP:UniProtKB.
DR   GO; GO:1903839; P:positive regulation of mRNA 3'-UTR binding; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0050434; P:positive regulation of viral transcription; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0006282; P:regulation of DNA repair; IDA:UniProtKB.
DR   GO; GO:0031056; P:regulation of histone modification; IDA:UniProtKB.
DR   GO; GO:0051147; P:regulation of muscle cell differentiation; IMP:UniProtKB.
DR   GO; GO:0031297; P:replication fork processing; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0042795; P:snRNA transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006368; P:transcription elongation from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Cytoplasm; DNA damage; DNA repair; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN         1    372       Cyclin-dependent kinase 9.
FT                                /FTId=PRO_0000085800.
FT   DOMAIN       19    315       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      25     33       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     104    106       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18566585}.
FT   REGION      166    191       T-loop.
FT   ACT_SITE    149    149       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      48     48       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18566585}.
FT   BINDING     167    167       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:18566585}.
FT   MOD_RES      29     29       Phosphothreonine.
FT                                {ECO:0000269|PubMed:10958691}.
FT   MOD_RES      44     44       N6-acetyllysine; by P300/CBP, PCAF/KAT2B
FT                                and GCN5/KAT2A.
FT                                {ECO:0000269|PubMed:17452463,
FT                                ECO:0000269|PubMed:18250157}.
FT   MOD_RES      48     48       N6-acetyllysine; by PCAF/KAT2B and
FT                                GCN5/KAT2A.
FT                                {ECO:0000269|PubMed:18250157}.
FT   MOD_RES     175    175       Phosphoserine.
FT                                {ECO:0000269|PubMed:21533037}.
FT   MOD_RES     186    186       Phosphothreonine; by CaMK1D.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:15965233,
FT                                ECO:0000269|PubMed:18483222,
FT                                ECO:0000269|PubMed:18566585,
FT                                ECO:0000269|PubMed:18829461,
FT                                ECO:0000269|PubMed:20535204,
FT                                ECO:0000269|PubMed:20851342,
FT                                ECO:0000269|PubMed:21448926,
FT                                ECO:0000269|PubMed:21779453}.
FT   MOD_RES     347    347       Phosphoserine; by CDK9 and PKA.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:10958691,
FT                                ECO:0000269|PubMed:18566585}.
FT   MOD_RES     350    350       Phosphothreonine; by CDK9.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:10958691}.
FT   MOD_RES     353    353       Phosphoserine; by CDK9.
FT                                {ECO:0000269|PubMed:10958691}.
FT   MOD_RES     354    354       Phosphothreonine; by CDK9.
FT                                {ECO:0000269|PubMed:10958691}.
FT   MOD_RES     357    357       Phosphoserine; by CDK9.
FT                                {ECO:0000269|PubMed:10958691}.
FT   MOD_RES     362    362       Phosphothreonine; by CDK9.
FT                                {ECO:0000269|PubMed:18566585}.
FT   MOD_RES     363    363       Phosphothreonine; by CDK9.
FT                                {ECO:0000269|PubMed:18566585}.
FT   VAR_SEQ       1      1       M -> MQRDAPPRAPAPAPRLPAPPIGAAASSGGGGGGGSG
FT                                GGGGGASAAPAPPGLSGTTSPRGPGGGRRAEEAGSAPRGRK
FT                                WPWRRKWRGRGGAWSAAAAGPGAGAAAAATGGGGGALEAAM
FT                                (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_016288.
FT   VARIANT      59     59       F -> L (in dbSNP:rs55640715).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041982.
FT   VARIANT     231    231       G -> A. {ECO:0000269|PubMed:10903437,
FT                                ECO:0000269|PubMed:7695608}.
FT                                /FTId=VAR_013456.
FT   MUTAGEN      44     44       K->R: Impaired kinase and transcriptional
FT                                elongation activities, but normal cyclin
FT                                T1 and HEXIM1 binding.
FT                                {ECO:0000269|PubMed:17452463}.
FT   MUTAGEN     167    167       D->N: Abrogates kinase activity.
FT                                {ECO:0000269|PubMed:10958691,
FT                                ECO:0000269|PubMed:11145967}.
FT   MUTAGEN     175    175       S->A: Constitutive kinase activity.
FT                                {ECO:0000269|PubMed:21533037}.
FT   MUTAGEN     175    175       S->D: Mimics phosphorylation,
FT                                constitutive loss of kinase activity.
FT                                {ECO:0000269|PubMed:21533037}.
FT   MUTAGEN     186    186       T->A: Abrogates autophosphorylation; no
FT                                effect on kinase activity, but impaired
FT                                CTD phosphorylation.
FT                                {ECO:0000269|PubMed:11145967,
FT                                ECO:0000269|PubMed:18566585,
FT                                ECO:0000269|PubMed:21448926}.
FT   MUTAGEN     186    186       T->D: Mimics autophosphorylation;
FT                                constitutive kinase activity,
FT                                independently of calcium signaling.
FT                                {ECO:0000269|PubMed:11145967,
FT                                ECO:0000269|PubMed:18566585,
FT                                ECO:0000269|PubMed:21448926}.
FT   MUTAGEN     347    357       SQITQQSTNQS->AQIAQQAANQA: Loss of
FT                                autophosphorylation and impaired
FT                                interaction with HIV TAT.
FT                                {ECO:0000269|PubMed:10958691}.
FT   MUTAGEN     347    357       SQITQQSTNQS->EQIEQQEENQE: Mimics
FT                                autophosphorylation and promotes
FT                                interaction with HIV TAT.
FT                                {ECO:0000269|PubMed:10958691}.
FT   CONFLICT    163    163       L -> P (in Ref. 4; AAV38706).
FT                                {ECO:0000305}.
FT   STRAND       13     15       {ECO:0000244|PDB:4EC9}.
FT   HELIX        16     18       {ECO:0000244|PDB:3MI9}.
FT   STRAND       19     24       {ECO:0000244|PDB:3MI9}.
FT   STRAND       28     30       {ECO:0000244|PDB:3BLR}.
FT   STRAND       32     38       {ECO:0000244|PDB:3MI9}.
FT   TURN         39     41       {ECO:0000244|PDB:3MI9}.
FT   STRAND       44     49       {ECO:0000244|PDB:3MI9}.
FT   STRAND       56     59       {ECO:0000244|PDB:3MI9}.
FT   HELIX        61     72       {ECO:0000244|PDB:3MI9}.
FT   STRAND       81     87       {ECO:0000244|PDB:3MI9}.
FT   STRAND       98    104       {ECO:0000244|PDB:3MI9}.
FT   STRAND      107    109       {ECO:0000244|PDB:3MI9}.
FT   HELIX       110    115       {ECO:0000244|PDB:3MI9}.
FT   STRAND      116    118       {ECO:0000244|PDB:3LQ5}.
FT   HELIX       123    142       {ECO:0000244|PDB:3MI9}.
FT   HELIX       152    154       {ECO:0000244|PDB:3MI9}.
FT   STRAND      155    157       {ECO:0000244|PDB:3MI9}.
FT   STRAND      163    165       {ECO:0000244|PDB:3MI9}.
FT   HELIX       168    170       {ECO:0000244|PDB:4OGR}.
FT   STRAND      178    181       {ECO:0000244|PDB:3MI9}.
FT   HELIX       192    194       {ECO:0000244|PDB:3MI9}.
FT   HELIX       197    200       {ECO:0000244|PDB:3MI9}.
FT   HELIX       209    224       {ECO:0000244|PDB:3MI9}.
FT   HELIX       234    245       {ECO:0000244|PDB:3MI9}.
FT   TURN        250    252       {ECO:0000244|PDB:3MI9}.
FT   HELIX       256    258       {ECO:0000244|PDB:3MI9}.
FT   HELIX       260    262       {ECO:0000244|PDB:3MI9}.
FT   HELIX       263    265       {ECO:0000244|PDB:3MY1}.
FT   HELIX       275    283       {ECO:0000244|PDB:3MI9}.
FT   HELIX       286    295       {ECO:0000244|PDB:3MI9}.
FT   HELIX       300    302       {ECO:0000244|PDB:3MI9}.
FT   HELIX       306    310       {ECO:0000244|PDB:3MI9}.
FT   HELIX       313    316       {ECO:0000244|PDB:3MI9}.
FT   STRAND      317    319       {ECO:0000244|PDB:3MI9}.
FT   HELIX       325    329       {ECO:0000244|PDB:3MI9}.
FT   HELIX       335    339       {ECO:0000244|PDB:3MI9}.
SQ   SEQUENCE   372 AA;  42778 MW;  69E851CC6F7A0388 CRC64;
     MAKQYDSVEC PFCDEVSKYE KLAKIGQGTF GEVFKARHRK TGQKVALKKV LMENEKEGFP
     ITALREIKIL QLLKHENVVN LIEICRTKAS PYNRCKGSIY LVFDFCEHDL AGLLSNVLVK
     FTLSEIKRVM QMLLNGLYYI HRNKILHRDM KAANVLITRD GVLKLADFGL ARAFSLAKNS
     QPNRYTNRVV TLWYRPPELL LGERDYGPPI DLWGAGCIMA EMWTRSPIMQ GNTEQHQLAL
     ISQLCGSITP EVWPNVDNYE LYEKLELVKG QKRKVKDRLK AYVRDPYALD LIDKLLVLDP
     AQRIDSDDAL NHDFFWSDPM PSDLKGMLST HLTSMFEYLA PPRRKGSQIT QQSTNQSRNP
     ATTNQTEFER VF
//
